1. Reimer RR, Clark WH Jr, Greene MH, Ainsworth AM, Fraumeni JF Jr. Precursor lesions in familial melanoma: A new genetic preneoplastic syndrome. JAMA. 1978;239(8):744–6.   

2. Green MH, Reimer RR, Clark WH Jr, Mastrangelo MJ. Precursor lesions in familial melanoma. Semin Oncol 1978;5(1): 85–7.

3. Ackerman AB, Cerroni L, Kerl H. Pitfalls in Histopathologic Diagnosis of Malignant Melanoma. Lea & Febiger, Philadelphia, 1994.

4. Friedman RJ, Rigel DS, Kopf AW. Early detection of malignant melanoma. CA. 1985;35:130–51.   

5. Dixon SL and Ackerman AB. Editorial. Some observations, reflections, and questions about dysplastic nevi. Am J Dermatopathol 1985;7:A17–A25 (Supplement).

6. Ackerman AB, Magana-Garcia M. Naming acquired melanocytic nevi: Unna's, Miescher's, Spitz's, Clark's. Am J Dermatopathol 1990;12:193–209.   

7. Ackerman AB and Mihara I. Dysplasia, dysplastic melanocytes, dysplastic nevi, the dysplastic nevus syndrome, and the relation between dysplastic nevi and malignant melanomas. Human Path 1985;16:87–91.

8. Ackerman AB, Su WPD. The histology of cutaneous malignant melanoma. In Kopf AW, Bart RS, Rodriguez-Saius RS, Ackerman AB, ed. Malignant Melanoma. New York, Masson, 1979:25–147.

9. Elder DE, Green MH, Bondi EE, Clark WH Jr. Acquired melanocytic nevi and melanoma. The dysplastic syndrome. In Ackerman AB, ed. Pathology of Malignant Melanoma. New York, Masson, 1981:185–215.

10. Questions to the editorial board and other authorities. Am J Dermatopathol 1985;7:213–25 (Supplement).

11. Ackerman AB. What nevus is dysplastic, a syndrome, and the commonest precursor of malignant melanoma? A riddle and an answer. Histopathol 1988;13:241–56.   

12. Clark WH Jr, Ackerman AB. An exchange of views regarding the dysplastic nevus controversy. Semin Dermatol. 1989;8(4):229–50.   

13. Nollet DJ. Clark's nevus syndrome [letter]. Am J Dermatopathol 1986;8(4):367.   

14. NIH Consensus Development Conference. Katz SI, ed. Precursors to malignant melanoma. Am J Dermatopathol. 1984; 6(suppl):169–74.

15. Lynch HT, Fusaro RM, Albano WA, Pester J, Kimberling WJ, Lynch JF. Phenotypic variation in the familial atypical mole-melanoma syndrome (FAMMM). J Med Genet. 1983;20(1): 25–9.   

16. Kraemer KH, Greene MH, Tarone R, Elder DE, Clark WH Jr, Guerry D. Dysplastic naevi and cutaneous melanoma risk [letter]. The Lancet. 1983;2(8358):1076–7.   

17. English DR, Menz J, Heenan PJ, Elder DE, Watt JD, Armstrong BK. The dysplastic nevus syndrome in patients with cutaneous melanoma. Med J Aust. 1986;145(5):194–8.   

18. Maize JC, Ackerman AB. Pigmented lesions of the skin. Clinicopathologic Correlations. Philadelphia, Lea & Febiger, 1987:73–84.

19. Marks R, Dorevitch AP, Mason G. Do all melanomas come from "moles?" A study of the histological association between melanocytic naevi and melanoma. Australas J Dermatol. 1990;31(2):77–80.   

20. Hastrup N, Osterlind A, Drzewiecki KT, Hou-Jensen K. The presence of dysplastic nevus remnants in malignant melanomas. A population-based study of 551 malignant melanomas. Am J Dermatopathol. 1991:13(4):378–85.

21. Ainsworth AM, Folberg R, Reed RJ, Clark WH Jr. Melanocytic nevi, melanocytomas, melanocytic dysplasias, and uncommon forms of melanoma. In Clark WH Jr, Goldman LI, Mastrangelo MJ, eds. Human Malignant Melanoma. New York, Grune & Stratton, 1979:167–208.

22. Clark WH Jr, From L, Bernardino EA, Mihm MC. The histogenesis and biologic behaviour of primary human malignant melanomas of the skin. Cancer Res. 1969;29(3):705–27.   

23. Ackerman AB and Elder DE. An exchange of ideas about dysplastic nevi and malignant melanoma. Am J Dermatol 1985;7:99–105 (Supplement).

24. Clark WH, Goldstein AM, Tucker MA. Perspectives for cutaneous malignant melanoma: Consideration of the precursor state and hereditability. Br Med Bull. 1995;51:717–746.